Skip to content
Early Development and The Dose Selection in the Immune-oncology episode artwork

Dec 16, 2024 19 min

Early Development and The Dose Selection in the Immune-oncology

from The Effective Statistician - in association with PSI Hosted by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry

How do we find the right dose in immune-oncology trials? Is the traditional “maximum tolerated dose” approach still enough, or should we also focus on efficacy? In this episode of The Effective Statistician, I talk with Teppo Huttunen, a seasoned statistician and co-founder of the boutique CRO, Estimeds. We uncover the shortcomings of the conventional three-plus-three design and explain how the Bayesian Optimal Interval (BOIN) design gives us more flexibility and better insights. Teppo shares practical tips on dose optimization and highlights the critical role statisticians play in shaping smarter, evidence-based decisions for phase two trials. If you want to learn how we can balance safety, efficacy, and practical challenges in oncology studies, this episode is for you!

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Early Development and The Dose Selection in the Immune-oncology

0:00 19:28

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Effective Statistician - in association with PSI?

This episode is 19 minutes long.

When was this The Effective Statistician - in association with PSI episode published?

This episode was published on December 16, 2024.

Can I download this The Effective Statistician - in association with PSI episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.